According to a new article, the main ingredient The best sales drugs I can help people Treat severe liver disease Before it becomes a threat to life. Results, released on Wednesday New England JournalThey are the most recent proof that slim medication, such as osemic or vagovi, can help treat other health problems in addition to diabetes and obesity, which is currently recognized in the EU.
The Semagludida It belongs to a type of drugs called the Akonnists of the GLP -1 receptors, which operate by suppressing appetite. But Inquiry suggests It also helps with different problems such as addiction, blood clotting and old age. Now, the new study shows that they may be a potential treatment for patients Stedohepatitis Related to metabolic dysfunction (EMA), which occurs when fat accumulates in the liver and causes scars.
If not, it may develop ChirosisIt is an advanced and irreversible liver damage. Mesh is not related to alcohol, but obesity, type 2 diabetes and hypertension. The drug funded for advanced phase medical examination Novo NordiskIt sells the semagludida osembic and vast. They participated in it 800 patients with mash and liver fibrosis Moderate or advanced, ie accumulation of scar tissue in the liver.
Good results after 72 weeks
72 weeks later, 33% of patients who have taken semaglutida Once a week they experienced improvements in both swelling and liver healing, compared to 16% of those who have received pharmaceutical or fantasy treatment. Regarding inflammation and separate healing, about 63% of patients who took semaculida reduced inflammation and 37% of people noticed the healing improvement.
It is compared to 34% and 22% of the pharmaceutical group, respectively. In addition, patients taken Semagludida lost an average of 10.5% of their body weight. The results of the study They are “very exciting”Tebi Shogros, a doctor and professor of chronic liver failure at Kings College (United Kingdom) of Kings College (United Kingdom) (United Kingdom) (United Kingdom).
But not all qualifications have been carried out because patients with pharmaceuticals and pharmaceutical groups They received suggestions on lifestyle And recommendations on how to control your other health problems. Approximately half of the study suffered from Type 2 diabetes, and three out of four were obese.
According to Shakrose, 34% of the participants in the pharmaceutical group reduced their liver disease – without losing a lot of weight – suggests that Changes of the lifestyle may also occur The key role in helping people to control Mesy.
“This is important because any treatment is recognized to make mash with a moderate first intense fibrosis It should be used in accordance with lifestyle interventions“He told Shagraz, who did not participate in the new study. Adverse effects 2.6% of them left the study.
A new potential treatment for Mesh
When the Novo Nordisk article released the main results on November 2024, the company said I will listen to the EU and the US regulatory authorities. This will be approved by Mash patients in mid -2012. At the time, the company’s doctor and administrator Martin Holst Lange said the drug would help hide “Important Need Need” Mash patients.
The spokesman for Novo Nordiskin did not respond to the request of ‘EuroNius Health’ on Wednesday, in which the deadline for the deadline was requested. No medicine has ever been recognized in the EU To treat Mash, but others have been promising in recent years. For example, RessMerome, an advanced phase test released last year, has helped improve the liver healing and has a green light in the United States.
This is still being studied by EU regulatory authorities. Shakrose said that it was too soon to know If it is possible to change the rules of the semaglutida game For mash patients, but “If used in accordance with lifestyle, this is undoubtedly a powerful tool in the hepatologist Arsenal.”
He pointed out that many people who take the drug to reduce body weight They do not introduce changes in their lifestyle If they stop taking them, they may help improve their health, which is “important concern to all of us.” “There are many motivations for patients close to the experiment Positive changes in your lifestyle It may not be seen in the real world, ”Shakrose said.
